Raphael Pharmaceutical (RAPH) Gains from Investment Securities (2022 - 2025)

Raphael Pharmaceutical has disclosed Gains from Investment Securities across 4 years of filings, most recently posting $1.0 million for Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at $1.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 million (changed 0.0% YoY), and the FY2025 annual result was $1.0 million, changed 0.0% from the prior year.
• Gains from Investment Securities came in at $1.0 million for Q4 2025 at Raphael Pharmaceutical, roughly flat from $1.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.0 million in Q4 2022 to a low of $1.0 million in Q4 2022.
• The 4-year median for Gains from Investment Securities is $1.0 million (2022), against an average of $1.0 million.
• Peak annual rise in Gains from Investment Securities reached 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
• Raphael Pharmaceutical's Gains from Investment Securities stood at $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
• The last three Gains from Investment Securities figures came in at $1.0 million (Q4 2025), $1.0 million (Q4 2024), and $1.0 million (Q4 2023), per Business Quant data.